DRTS
Alpha Tau Medical Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$15.03
+2.80%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -53.8%
- EBIT
- -34.4%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +114.0%
- EPS
- +44.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- -35.3%
- EBIT
- -17.3%
- Net income
- -34.3%
- EPS
- -17.8%
- Free cash flow
- -48.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026